Physicians' Academy for Cardiovascular Education
A study demonstrated that traditional CV factors (BMI, SBP, total cholesterol level, triglyceride level, and smoking) in childhood are associated with CV events during adulthood.
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.
Does the type or lipid content of apoB-containing lipoprotein carry any additional risk of MI beyond the total number of apoB-containing lipoproteins?
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.
The PROMINENT study, which investigated whether pemafibrate could reduce CV outcomes by reducing triglycerides in patients with T2DM, will be stopped early.
ACC 2022 Treatment with vupanorsen, the antisense oligonucleotide (ASO) targeting ANGPTL3 mRNA, resulted in reduced non-HDL-c and TG levels at all doses, but apoB was modestly reduced. Importantly, there were key safety and tolerability findings with vupanorsen.
In a cohort study, number of apoB-containing lipoprotein captures risk of myocardial infarction best, and this association is independent from lipid content (cholesterol or TG) or type (LDL or TG-rich) of lipoprotein.
A study found clinically meaningful differences in LDL-c values estimated by the Friedewald, Sampson, and Martin/Hopkins equations, especially in patients with TG levels ≥150 mg/dL and at lower LDL-c values.
Olezarsen is a (GalNAc)-conjugated, antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apoC-III. This phase 2 study investigated the effect of apoC-III inhibition by olezarsen on triglyceride levels.
Prof. Daniel Gaudet gives an overview of emerging therapies targeting triglyceride-rich remnant lipoproteins. With question to test your knowledge.
The TRANSLATE-TIMI 70 trial, a dose-ranging phase 2b study with the ANGPTL3 antisense vupanorsen in subjects with dyslipidemia, met its primary endpoint: a significant reduction of non-HDL-c at 24 weeks with vupanorsen compared to placebo.
